Christine Cassiano

Christine Cassiano is the Chief Communications Officer of Allogene. She is a communications executive with wide experience in investor relations, corporate communications, media relations, brand strategy and public affairs. Christine previously served as Senior Vice President of Corporate Communications and Investor Relations for Kite until its acquisition by Gilead Sciences in 2017. Christine’s career is distinguished by the development of integrated communications strategies for companies with novel therapies such as YescartaTM (axicabtagene ciloleucel) and Botox®/Botox® Cosmetic (onabotulinumtoxinA). She has held executive management positions in international communications agencies, including roles as the Head of Healthcare for W2O and Senior Vice President and Co-Director, Healthcare, at Hill + Knowlton Strategies. Christine co-founded ARC2 Communications & Media, a boutique agency that developed groundbreaking platforms for some of the largest companies in healthcare. She has also held senior global communications roles in biotechnology and pharmaceutical companies, including Amgen, Allergan and Abraxis BioScience. Some of Christine’s career achievements include a SABRE Silver Anvil award for the launch of Botox® Cosmetic (Allergan), an In2 SABRE Award for the Most Innovative Brand/Agency Collaboration (Pfizer/ARC2), and PR Week’s 40 Under 40. Christine also serves as a Senior Strategic Advisor to Urogen Pharma, Kronos Bio and Vida Ventures. She holds a B.A. from California State University, Fullerton and Investor Relations Certification (IRC) from the University of California, Irvine.